Navigation Links
Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange

EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") Quest is pleased to provide an update on the pre-clinical development of SL052 for the treatment of prostate cancer.

Prostate cancer is the second leading cause of cancer death in American men with approximately 230,000 new cases and 30,000 deaths per year. Current therapeutic modalities for localized prostate cancer are associated with significant morbidity, such as sexual and urinary dysfunction. Photodynamic therapy (PDT) is a minimally invasive treatment that may be used in benign and malignant prostate diseases. PDT is a dual selective treatment modality using light of a specific wavelength to locally activate a photosensitizer accumulated in the target tissue. This novel therapy causes a non-carcinogenic photochemical destruction of cancer cells, including those that are resistant to radiation and chemotherapy.

Quest's innovative Photodynamic Therapy (PDT) prostate cancer treatment system utilizes our patented Sonolight Technology, our proprietary and potent Hypocrellin based photosensitizer, SL052, with a novel intra-arterial drug delivery system and state of the art laser device that delivers pulsed light. Pre-clinical studies in small and large animals have demonstrated the effectiveness of SL052 in selective destruction of normal and cancerous prostate tissues, with minimal side effects. The use of 18 F FDG (flurodeoxy glucose) PET imaging pre and post PDT treatment, highlighted the complete shut down of metabolic activity at the tumor site 24 hours after PDT treatment.

The practical application of this new PDT treatment system on the prostate gland has also been demonstrated using a canine prostate model. The intra-arterial drug delivery system allows the selective and significant accumulation of the photosensitizer in the prostate which is ea
'"/>




Page: 1 2 3

Related medicine technology :

1. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. To Stent or Not: Is That the Question?
4. VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
7. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
10. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Quest PharmaTech Prostate Cancer Program Update
(Date:6/20/2013)... WESTMINSTER, Colo. , June 20, 2013 ... Surefire Medical today announced a sales and marketing partnership ... catheters for the interventional radiology and oncology markets. ... range of products in the company,s rapidly growing ... . Sirtex reported a 30 per cent growth ...
(Date:6/20/2013)... , June 20, 2013 Today ... mark the launch of a new programme to control the ... Jacobina in the State of Bahia. In previous ... is possible to rapidly reduce the number of dengue mosquitoes ... the level of these mosquitoes were reduced by 96% within ...
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... suggested ibrutinib may be effective and generally well-tolerated in ... a separate study examining the safety and efficacy of ...
Breaking Medicine Technology:Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6
... Emdeon Inc. (NYSE: EM ), a leading provider ... acquisition of Chapin Revenue Cycle Management, LLC ("Chapin"). Based in ... revenue cycle services including accounts receivable management, medical denials, appeals and ... , ...
... June 21 TMS Health, a leading Healthcare Communications Company ... PA. , , ... TMS Health has enjoyed strong growth as a specialized healthcare ... and marketing reach of its clients. The company provides solutions for ...
Cached Medicine Technology:Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4TMS Health Announces New State-of-the Art Facility in Moosic, PA 2
(Date:6/20/2013)... The ISA (International Seabuckthorn Association) founded ... announced their 6th annual international conference to take place ... , Bruce McMullin , Founder and CEO of ... for introducing the benefits of sea buckthorn to the ... Sibu grows and harvests sea buckthorn berries in the ...
(Date:6/20/2013)... Indianapolis, IN (PRWEB) June 20, 2013 ... Many employers are concerned that this cost percentage will ... burden of caring for both aging parents and adult ... claims management can either provide workers a road block, ... , United Benefit Advisors (UBA), in ...
(Date:6/20/2013)... York, New York (PRWEB) June 20, 2013 ... protein folding and misfolding, Navneet Tyagi has ... Alzheimer’s disease. Throughout the myriad of scientific research that ... his commitment of identifying early onset of these severe ... through early diagnosis, more medical researchers will be able ...
(Date:6/20/2013)... Denton, TX (PRWEB) June 20, 2013 ... has maintained a wide range of outpatient and inpatient ... psychiatric issues, including those who are children. As a ... UBH explains that it is critical to diagnose mental ... action. However, according to a recent article ...
(Date:6/20/2013)... June 20, 2013 Rampant staph infections ... to fight this scourge is being successfully deployed by ... direct contact and by touching items that are contaminated ... As noted by the San Francisco Chronicle , ... become infected during hospital stays, and at least 90,000 ...
Breaking Medicine News(10 mins):Health News:Sibu, LLC CEO, Bruce McMullin to be Amongst Distinguished Attendees at ISA Conference 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 2Health News:United Benefit Advisors and Symetra Host Absence Management Webinar 3Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 2Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 3Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 2Health News:New Statistics Indicate Increase in Mental Health Issues Among Children, UBH Denton Responds 3Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 2Health News:Lab Testing Reveals EnviroTextile's Hemp Fabric Stops the Spread of Staph Bacteria 3
... gene respond well to targeted therapy , , SUNDAY, June ... the normal version of a particular gene are more ... adding the targeted therapy Erbitux to chemotherapy. , Some ... "wild-type" form of the gene, according to the new ...
... cells, hasten death, study says , , SUNDAY, June 1 ... in cancer patients may actually speed progression of the ... found a way to determine who those individuals are. ... whether a patient is susceptible to having their tumor ...
... study suggests , , SUNDAY, June 1 (HealthDay News) -- ... value in helping to prevent lung cancer. , Researchers ... on the U.S. market, may reduce levels of a ... presented its findings Sunday at the American Society of ...
... combination of two different biotherapies may be beneficial for ... Pittsburgh Cancer Institute (UPCI) study presented at the 44th ... (ASCO) in Chicago. , Researchers in the melanoma and ... treatments that stimulate the immune system to fight cancer ...
... common types, study says , , SUNDAY, June 1 (HealthDay News) ... or adolescents are much more likely than other people to ... disease (HD), a cancer of the lymph nodes, has a ... be at future risk of developing second cancers other than ...
... in determining how much fathers get involved in taking care ... of 97 couples found that fathers were more involved in ... encouragement from their wife or partner. , In fact, this ... mothers views about how involved dads should be, the overall ...
Cached Medicine News:Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2Health News:Mom's behavior key to dad's involvement in child care 2Health News:Mom's behavior key to dad's involvement in child care 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: